Screener
Neuropace, Inc. NPCE Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $22.83M+17.1% | $22.07M-2.0% | $26.59M+23.9% | $27.35M+29.9% | $19.5M+1.3% | ||
| $3.92M+19.2% | $4.02M-22.4% | $6.01M+13.9% | $6.19M+9.7% | $3.29M-35.8% | ||
| $18.91M+16.6% | $18.05M+4.1% | $20.58M+27.1% | $21.17M+37.3% | $16.21M+14.7% | ||
| 82.8%-0.3pp | 81.8%+4.8pp | 77.4%+2.0pp | 77.4%+4.2pp | 83.1%+9.7pp | ||
| $6.9M+0.8% | $7.19M-3.4% | $7.03M+16.1% | $6.58M+14.3% | $6.85M+12.9% | ||
| $12.12M+5.5% | $11.58M+5.3% | $10.94M+9.9% | $12.6M+26.9% | $11.49M+17.8% | ||
| $5.03M-17.2% | $4.84M+19.7% | $4.38M+14.1% | $4.59M+15.4% | $6.07M+33.6% | ||
| $24.05M-1.4% | $23.62M+5.0% | $22.35M+12.6% | $23.77M+20.9% | $24.4M+19.8% | ||
| -$5.14M+37.2% | -$5.57M-8.2% | -$1.77M+51.6% | -$2.6M+38.7% | -$8.19M-31.4% | ||
| -22.5%+19.5pp | -25.2%-2.4pp | -6.6%+10.4pp | -9.5%+10.6pp | -42%-9.6pp | ||
| $1.54M-25.3% | $1.52M-29.4% | $1.6M-27.0% | $1.65M-24.6% | $2.06M-4.9% | ||
| -$41K+91.6% | -$165K-101% | $0— | $82K-62.6% | -$486K-505% | ||
| -$6.2M+28.3% | -$6.69M-1.5% | -$2.73M+48.0% | -$3.5M+35.9% | -$8.65M-15.1% | ||
| -27.2%+17.2pp | -30.3%-1.1pp | -10.3%+14.2pp | -12.8%+13.1pp | -44.4%-5.3pp | ||
| -$0.18+30.8% | -$0.20+4.8% | -$0.08+52.9% | -$0.11+42.1% | -$0.260.0% | ||
| -$5.04M+37.7% | -$5.51M-8.0% | -$1.69M+53.2% | -$2.5M+39.7% | -$8.09M-32.0% | ||
| -22.1%+19.4pp | -25%-2.3pp | -6.3%+10.4pp | -9.1%+10.5pp | -41.5%-9.6pp | ||
| -$5.14M+37.2% | -$5.57M-8.2% | -$1.77M+51.6% | -$2.6M+38.7% | -$8.19M-31.4% |
FAQ
- What is Neuropace, Inc.'s revenue?
- Neuropace, Inc. (NPCE) generated $98.8M in revenue over the trailing twelve months, up 16.9% year over year.
- Is Neuropace, Inc. profitable?
- Neuropace, Inc. is not currently profitable: it reported a net loss of $19.1M over the trailing twelve months, a -19.3% net margin.
- What are Neuropace, Inc.'s profit margins?
- Gross margin is 79.6% and operating margin is -15.3%, with a -19.3% net margin.
- What is Neuropace, Inc.'s earnings per share?
- Neuropace, Inc.'s diluted EPS over the trailing twelve months is $-0.57.
- Where does Neuropace, Inc.'s income statement data come from?
- Every line is extracted from Neuropace, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
